Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571

Chen, Teng-Wei; Liu, Hsiao-Dung; Shyu, Rong-Yaun; Yu, Jyh-Cherng; Shih, Ming-Lang; Chang, Tzu-Ming; Hsieh, Chung-Bao

doi:10.3748/wjg.v11.i2.260

Cited by 18 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the intimate relationship of R0 resection and tumor size, the ultimate significance of margin status for GIST is controversial as some investigators have found it to be a significant prognostic indicator of overall outcomes, whereas others have failed to find any significance in terms of RFS or OS . A more recent review of 819 patients undergoing resection for primary GIST from the North American branch of the American College of Surgeons Oncology Group Z9000 and Z9001 clinical trials analyzed factors associated with R1 resection and assessed the risk of recurrence with and without imatinib .…”

Section: Discussionmentioning

confidence: 99%

The accuracy of three predictive models in the evaluation of recurrence rates for gastrointestinal stromal tumors

Racz

Brar

Cleghorn

et al. 2014

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The accuracy of three predictive models in the evaluation of recurrence rates for gastrointestinal stromal tumors

Racz

Brar

Cleghorn

et al. 2014

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…En bloc resection is advised for GISTs that are adherent to nearby structures(34). The goal is to achieve negative microscopic margins; positive margins are associated with a risk of peritoneal recurrence(35). In one case series(36), the disease-specific survival rate at five years for resectable GIST was 54%; median survival was 66 months.…”

mentioning

confidence: 99%

Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment

Blackstein

Blay

Corless

et al. 2006

Canadian Journal of Gastroenterology

123

View full text Add to dashboard Cite

In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate the efforts of pathology, radiology, surgery and oncology. Surgery is the mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with a risk of metastasis. Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present with specific genotypic characteristics. Adjuvant or neoadjuvant imatinib is not advised for resectable nonmetastatic GISTs. Neoadjuvant imatinib may be considered when surgery would result in significant morbidity or loss of organ function. Follow-up computed tomography imaging is recommended every three to six months for at least five years. Patients with metastatic disease should be continued on imatinib due to the high risk of recurrence on discontinuation of therapy. Treatment should be continued until there is progression or intolerable adverse effects. If dose escalation with imatinib fails, a clinical trial with novel agents alone or in combination may be considered. The present recommendations were developed at a surgical subcommittee meeting and a subsequent full Advisory Committee meeting held in Toronto, Ontario, in April 2005, under the sponsorship of Novartis Pharmaceuticals Canada Inc.

show abstract

“…GIST usually spreads by direct extension to adjacent structures and hematogenously to the liver, lung, and bone. Lymphatic metastasis is unusual [ 11 ]. GIST tumors have variable markers, including C-KIT (CD 117), DOG-1, CD 34, SMA, S100, and Desmin, of which, they are almost always positive for C-KIT and DOG 1 [ 3 , 5 , 12 – 14 ].…”

Section: Discussionmentioning

confidence: 99%

Primary Small Bowel GIST Presenting as a Life-Threatening Emergency: A Report of Two Cases

Khuri

Gilshtein

Darawshy

et al. 2017

Case Reports in Surgery

View full text Add to dashboard Cite

Gastrointestinal stromal tumor (GIST) is a rare stromal neoplasm, which represents the most common mesenchymal tumor of the gastrointestinal tract. It is characterized by indolent clinical symptoms, although it can present as a life-threatening emergency. Herein, we present two cases of primary small bowel GIST treated at our department. A 68-year-old female patient presented to our emergency department with a diffuse abdominal pain of acute onset. Imaging studies revealed a mass at proximal jejunum, with a nearby free air and fluid. At surgery, a mass of 9 cm was found at proximal jejunum, 3 cm distal to the treitz ligament, with perforation on the lateral wall of the mass. En bloc resection was performed. Pathology report was positive for gastrointestinal stromal tumor. A 70-year-old male patient presented to our emergency department with 3 days of dark tarry stool and few hours of hematochezia. Computed tomography angiography revealed a mass at the pelvis, with calcifications, attached to the distal ileum, with intraluminal blush of intravenous iodine. At surgery, a mass of 8 cm at the distal ileum was found. Resection of the mass along with a 20 cm of ileum was completed. Histopathology report was positive for malignant gastrointestinal stromal tumor.

show abstract

Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571

Cited by 18 publications

References 27 publications

The accuracy of three predictive models in the evaluation of recurrence rates for gastrointestinal stromal tumors

The accuracy of three predictive models in the evaluation of recurrence rates for gastrointestinal stromal tumors

Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment

Primary Small Bowel GIST Presenting as a Life-Threatening Emergency: A Report of Two Cases

Contact Info

Product

Resources

About